DAYTON, Ohio, Nov. 22 /PRNewswire/ -- Riverain Medical has introduced the first and only artificial intelligence system with FDA PMA approval for CHEST X-RAY early-stage Lung Cancer detection. In clinical trials, radiologists working with RapidScreen’s(R) computer aided detection technology demonstrated a 23% increase in detection efficiency for lung nodules ranging from 9 to 14mm in size. Detecting and treating more lung cancers in the earliest stage has the potential to save 54,000 lives annually. The RapidScreen(R) early Lung Cancer detection system is commercially available and will be at the RSNA - Radiological Society of North America 90th Scientific Assembly and Annual Meeting in Chicago from November 28 through December 3, 2004.
According to The American Cancer Society, Lung Cancer is the number one cancer killer in the United States. In the U.S. alone, an estimated 160,000 lives are lost each year to lung cancer -- more than colon, breast, and prostate cancer combined. Currently, only 15% of cancers are detected when they are small solitary pulmonary nodules in the 9-14 mm size. Small lung cancers found within this range present the most significant opportunity for earlier treatment for patients. It is estimated that Lung Cancer caught at this stage may be cured or controlled in up to 85% of all cases.
In clinical trials, radiologists working with RapidScreen(R) demonstrated a 23% increase in detection efficiency for lung nodules ranging from 9-14 mm in size. With over 71 million CHEST X-RAY exams given in the U.S. each year, early-stage Lung Cancer screening with RapidScreen(R) represents a tremendous opportunity to improve early detection and save additional lives. This tool can help radiologists detect more small, subtle, and suspicious nodules at an early stage.
“After initial screening and detection with RapidScreen(R) using routine CHEST X-RAYS, complementary technologies such as CT may be used to further characterize and confirm nodule identity,” states Matthew Freedman, MD, of Georgetown University Medical Center. Dr. Freedman, Professor of Oncology, is a pioneer in applying Computer Aided Detection (CAD) technology to early-stage Lung Cancer and a noted spokesman in the field. He adds, “CHEST X-RAY CAD enhances the value of the CHEST radiograph. Clinical trials have demonstrated that CAD prompt marks can increase the ability of radiologists to find suspicious nodules in routine X-RAYS.”
About Riverain Medical
Riverain Medical is a privately held corporation, located in Dayton, OH, that provides CHEST X-RAY CAD and medical artificial intelligence computer aided solutions to assist physicians in the detection of disease.
For more information on Riverain Medical and the RapidScreen(R) RS-2000 and RS-2000D products, please contact:
Greg Flittner, V.P. Marketing 937.425.6811 or 800.990.3387 gflittner@riveraingroup.com
Riverain Medical
CONTACT: Greg Flittner, V.P. Marketing of Riverain Medical,+1-937-425-6811, or +1-800-990-3387, or gflittner@riveraingroup.com
Web site: http://www.riverainmedical.com/